BofA upgraded Fresenius Medical (FMS) to Neutral from Underperform with a price target of EUR 45, up from EUR 35. Fresenius Medical Care’s key metrics of treatment volume, margin expansion and leverage “appear to have bottomed and started to inflect,” says the analyst, who thinks the the set-up for 2025 looks better than expected a year ago, while expectations on the sell-side remain “relatively low.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical added to European Conviction List at Goldman Sachs
- Fresenius Medical price target raised to EUR 41 from EUR 39 at Barclays
- Fresenius Medical’s Novalung ECMO System selected by Premier
- Fresenius Medical price target raised to EUR 39 from EUR 38.50 at Barclays
- Fresenius Medical price target raised to EUR 37.30 from EUR 35.40 at JPMorgan